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Abstract 
\Ve den1onstrate a con1putational network tnodel that integrates 18 in i'itro, high-
throughput screening assays measuring estrogen receptor (ER) binding, ditnerization, 
chromatin binding, transcriptional activation and ER-dependent cell proliferation. The 
net\vork model uses activity patterns across the in vitro assays to predict whether a 
chetnical is an ER agonist or antagonist, or is otherwise influencing the assays through a 
maimer dependent on the physics and che1nistry of the technology platfonn ("assay 
interference"). The method is applied to a library of 1812 commercial and environmental 
chc1nicals, including 45 ER positive and negative reference chemicals. Atnong the 
reference chemicals, the network n1odel correctly identified the agonists and antagonists 
\Vith the exception of very v.•eak co1npounds \Vhose activity \Vas outside the concentration 
range tested. The model agonist score also correlated with the expected potency class of 
the active reference chemicals. Of the 1812 chemicals evaluated, 111 (6.1%) were 
predicted to be strongly ER active in agonist or antagonist mode. This dataset and n1odel 
\Vere also used to begin a syste1natic investigation of assay interference. The 1nost 
prominent cause of false-positive activity (activity in an assay that is likely not due to 
interaction of the chemical with ER) is cytotoxicity. The 1nodel provides the ability to 
prioritize a large set of important environmental chemicals with human exposure 
potential for additional in vivo endocrine testing. Finally, this model is generalizable to 
any molecular path\vay for \Vhich there are 1nultiple l1pstrean1 and downstrean1 assays 
available. Disclai111er: The views e.\pressed in this paper are those of the authors and do 
not necessarily reflect the vieH'S or policies of the U.S. Environmental Protection Agency. 
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Introduction 
Signaling path\vays and nehvorks are key cornponcnts of complex biological 
systems. Endocrine signaling comn1ences \vhen hormones interact with their cognate 
receptors and initiate post-receptor functional responses. These important biological 
processes can be perturbed \Vhen xenobiotics either rnimic the action of the natural 
ligands or block the action of those ligands through antagonist action. These 
perturbations 1nay be purposely efficacious (e.g., phannaceuticals dosed within their 
therapeutic windo\v) or deleterious (e.g., environn1ental toxicants or oft:target high-dose 
interactions for pharmaceuticals). 
In order to measure the effect ofxenobiotics on signaling pathways and net\vorks, 
a variety of in vitro assays have been \vidcly used in dnig development and toxicity 
testing programs. These range from biochemical assays using purified protein to 1nore 
con1plex cellular assays that can respond to chemical perturbations in various ways. Each 
of these assays is subject to false positive and false negative results, some of\vhich are 
the result of"assay interference''. Conceptually, assay interference (Auld, Thon1e et al. 
2008, Baell and Holloway 2010, Thorne, Auld et al. 2010, Bn1ns and \Vatson 2012) is a 
phenomenon whereby assays designed to 1neasure binding to a protein or perturbation of 
a given pathWay may produce false signals when the target protein itself, or other 
path\vays in the syste1n, are altered non~specifically. The standard approach to deal \vith 
assay interference issues is to deploy "orthogonal" assays (Miller, Thanabal et al. 2010, 
Thon1e, Auld et al. 2010) that help distinguish activity towards the intended target or 
path\vay fron1 non-specific activities. In addition to assay interference issues, every assay 
has inherent limitations such as dyna1nic range or levels of background noise. Using a 
suite of assays to detect pathway perturbations may minimize potential non-specific 
effects or limitations of any single assay. 
In this sh1dy, \Ve evaluated ER pathway activity and assay interference using data 
from a collection of 18 in vitro assays that probe the estrogen receptor (ER) pathway in 
mammalian systems. These 18 in vitro assays are a subset of a larger collection of assays 
(821 individual assay endpoints) used in the EPA ToxCast program (Dix, Houck et al. 
2007, Judson, Houck ct al. 2010, Kavlock, Chandler et al. 2012). The 18 assays include 
biochenlical and cell-based in vitro assays that probe perturbations of ER path\vay 
responses at sites \Vithin the cell: receptor binding, receptor dimerization, chromatin 
binding of the 1nah1re transcription factor, gene transcription and changes in ER-induced 
cell gro\vth kinetics (Figure 1). The battery of 18 in vitro assays \Vas used to screen a 
library of 1812 chemicals. Included in the chemical library were reference chemicals, i.e., 
kt10\vn ER agonists and antagonists, as \Yell as a large number of commercial chemicals 
\Vith reported estrogen-like activity, so1ne of which are potentially selective estrogen 
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receptor n1odulators (SERMs) (Dutertre and Smith 2000, Katzenellenbogen, Choi et al. 
2000, Katzenellenbogen and Katzenellenbogen 2000, Katzenellenbogen, Montano et al. 
2000, Diel, Olffet al. 2001). 
The goal of this paper is to test the follo\ving hypothesis about the ER pathway 
and interference in the assays used to probe it. \Ve expect that there \Vill be sets of 
chemicals that are true ER agonists or antagonists, but that there will also be chemicals 
exhibiting a variety of types of assay interference (Inglese, Johnson et al. 2007, Thome, 
Auld et al. 2010, Hsieh, Sedykh et al. 2015) \Ve hypothesize that assay interference \Vill 
largely be technology-specific. For instance, a chemical could cause protein denaturation, 
\vhich could give rise to a false positive signal in cell-free, radioligand competitive 
binding assays. Such a chetnical \vould show activity in all assays of that technology, but 
not the cell-based assays. Another example would be fluorescent compounds, which 
would show false activity in all fluorescence-based assays. Therefore, given a very 
diverse set of chemicals and the diversity of cell types and technologies included in the 
battery of 18 in vitro assays, one could expect to see 1nany patterns of activity (i.e., 
vectors of activities for a chemical across 18 assays). To navigate this complexity, \Ve 
developed a 1nathematical I statistical model to infer \Vhether chemicals that activate 
specific patterns of the in vitro assays \Vere 1nore likely to be ER agonists, ER antagonists, 
or \Vere more likely to be causing assay activity through specific types of assay 
interference. Previous modeling approaches have been developed using a subset of the 
data presented here (Reif, Martin et al. 2010, Rotroff; Martin et al. 2014), but the current 
approach provides a 1nore generic model fra1ne\vork applicable to other signaling 
patlnvays beyond ER. Supplemental file Sl, Appendix 4 provides an overview of the 
differences behveen the Rotroff et al. model and the current one, and provides a 
quantitative comparison of the results. 
Understanding the results of this analysis \vill have three broad implications. First, 
the commercial chen1icals identified as ER-pathway actives can be prioritized for further 
testing as endocrine disn1ptors. Because such testing is expensive and time cons11ming, 
there is value in reducing false positives \Vithout significantly increasing false negatives 
using these in vitro screens. Second, che1nicals or chc1nical classes that show broad assay 
interference may potentially cause similar interference in other in vitro assays utilizing 
the same cell types or technology platfonns. These chen1icals can be flagged for extra 
scn1tiny \Vhen analyzing results for other targets. Finally, n1ethods developed for this test 
case can be applied to the analysis of results for other assays and patlnvays beyond the 
ER responses. 
Materials and Methods 
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Assays a11d Che11ticals: The input data for the nlodel includes che1nical structures and 
concentration-response data for 18 ER-related in vitro assays, plus data for nlany non-ER 
in vitro assay endpoints (ranging from 186-821 assays, depending on the chemical). The 
data used were generated by the EPA ToxCast progran1 (Dix, Houck et al. 2007, Judson, 
Houck et al. 2010). The dataset comprises concentration-response data on 1812 
chemicals with full data on ER patlnvay in vitro assays. These include 3 cell-free 
biochemical radioligand ER binding assays [Novascreen I NVS: (Knudsen, Houck et al. 
2011, Sipes, Martin et al. 2013)]; a set of 3 protein co1nplementation assays that measure 
formation of ER homodimers or heterodimers and test for activity against both ER-alpha 
and ER-beta, (each tneasured at 2 separate times for a total of6 assay readouts) [Odyssey 
Thera I OT:(Stossi, Bolt et al. 2014)]; 2 assays tneasuring interaction of green fluorescent 
protein (GFP)-tagged estrogen receptor a or ~ with nuclear DNA [Odyssey Thera I OT: 
(Stassi, Bolt et al. 2014)]; 2 transactivation assays measuring reporter RNA transcript 
levels [Attagene I ATG: (Martin, Dix et al. 2010)]; 2 transactivation assays measuring 
reporter protein level readouts in agonist mode and 2 transactivation assays in antagonist 
1node [Tox21: (Huang, Sakamuru et al. 2014)]; and an ER-sensitive cell proliferation 
assay [ACEA: (Rotroff, Dix et al. 2013)]. The transactivation assays are a mix of formats 
including differences in reporter gene technology (Tox21_ ERa_LUC _BG I :luciferase, 
Tox21 _ ERa _ BLA:~-lactamase, A TG _ERE_ CISI ATG _ ERa _ TRANS:mRNA) and 
differences in receptor form (Tox2l_ERa_LUC_BGl and ATG_ERE_ CIS are full length 
ER; Tox2l_ERa_BLA and ATG_ERa_TRANS are the GAL4/UAS tnamtnalian one 
hybrid system utilizing partial receptor constructs containing the receptor ligand-binding 
domain.) Use of these different formats allows one assay format to compensate for 
\Veaknesses inherent in another assay technology. The assay sources refer to the con1pany 
or laboratory \vhere the assays "''ere perfonned. The 18 in vitro assays used are 
summarized in Table 1 and more detail is given in Supplemental File SI, Appendix 1. 
The assay IDs correspond to Figure 1. The chemicals are listed in Supplemental File S2 
along \Vith summary results fro1n subsequent analyses. The chemicals \Vere ntn in 
concentration-response fonnat in all in vitro assays except for the cell-free binding assays 
(NVS). The NVS assays \Vere initially 11111 at a single concentration (25 µM), and if 
significant activity (3 median absolute deviations (~1AD) above the 1nedian or 30% 
activity) \Vas seen, the chemical "''as then n1n in concentration-response mode. 
Referellce che111icals: A set of 45 positive and negative reference chen1icals \Vere used to 
evaluate the performance of the model (described belo\v). These include 28 agonist 
positives, 12 agonist negatives, 4 antagonist positives and 14 antagonist negatives. Note 
that some chemicals are references for both agonist and antagonist mode, so these 
numbers sum to greater than 45. These chemicals have been used to validate ER in vitro 
assays and \Vere taken fron1 the OECD (Organisation for Econo1nic Cooperation and 
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Developn1ent) TG457 BGl guidance docurnent (OECD 2012). The reference che1nicals 
and their expected potencies are listed in Supplemental File S 1, Appendix 3. 
Data Processing and Synthetic Co11ce11tratio11-Response Data: All of the concentration-
response data were analyzed using a standardized data analysis pipeline, 'vhich automates 
the processes of baseline correction, nonnalization, curve-fitting, hit-calling and detection 
of a variety of potential confounders. This pipeline, along \Vith all of the raw and 
processed data, and annotations is publicly available 
[ http://epa.gov/ncctltoxcast/data.html and http://actor.epa.gov/edsp21]. All in vitro 
assays except those n111 by Attagene \Vere normalized to the range 0-100%, using the 
response of 17a-Ethinylestradiol. Attagene data were normalized as a fold-change over 
the solvent control (0.5-1% DMSO, \Vhich has been determined to have no effect on 
assay perfonnance) and then multiplied by a factor of 25 to yield a range of 
approximately 0-100. The data from each chemical-assay pair was flt to three models: a 
constant model, a Hi1l 1nodel, and a Gain-Loss model. The latter allo\VS the curve to rise 
from zero to a plateau, and then fall off again. This curve shape allo\ved us to account for 
non-specific assay interference, such as cytotoxicity occurring at high concentrations. 
Activity ("hit'') calls \Vere determined based on a chemical-assay pair reaching a set of 
significance thresholds: 
1. Median of normalized response values at a single concentration above the 
established response cutoff 
2. Modeled top (T) of the curve above the established response cutoff 
3. Hill or Gain-Loss n1odel \Vas the selected model over the constant model 
In order to establish the response cutoff, the baseline median absolute deviation (BMAD) 
'vas calculated per assay using the distribution of the lowest 2 concentration's normalized 
response values for all chemicals run in the in vitro assay. The response cutoff,vas then 
selected per assay as being the maxin1um of3-BMAD, 20% above baseline, or an assay-
specific cutoff, e.g., 6~BMAD or 10-BMAD. The Akaike Infonnation Criterion (Akaike 
1998) (AIC) was then calculated for each 1nodel, and the model with the lowest AIC was 
selected. For each model, the output included parameters as well as a number of 
diagnostics. The diagnostics \Vere assigned to specific chetnical sa1nple-assay pairs and 
indicate the presence of potential confounding factors such as curves that are marginally 
active and hence could be the result of non-normally distributed background noise instead 
oftn1e activity. An AC50 (activity concentration at half~maximal response}, Hill-slope, 
and 1naximu1n activity (T or Top value) \Vere extracted. To allo\v computational 
synthesis across different in vitro assays with different experimental designs (i.e., 
different nu1nbers of concentrations tested), a set of synthetic concentration-response 
activities \Vas generated through interpolation for each chemical-assay pair at 
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standardized concentrations. This procedure used the experimentally derived AC50, Hill-
slope and Top parameters and a Hill equation. All AC50 values \Vere in CM, and the 
synthetic concentrations \Vere a 1.5-fold dilutions series of 45 concentrations fron1 1 pM 
to!OOCM. 
Acco11uti11g for cytotoxicity-related assay i11te1fere11ce: For inany chemicals, \Ve 
observed a large number of hits (positive assay responses) for ER and non-ER assays in 
the concentration range \Vhere cytotoxicity was observed. Cytotoxicity \vas measured 
using a collection of 35 assays in the ToxCast battery that detect cytotoxicity or other 
forms of cell loss across several cell lines and primary cell types. Many non-selective 
cellular responses are activated as the concentration tested reaches a critical point 
associated \Vith cell stress or cytotoxicity. It appears that this is non-selective activity 
(assay interference) rather than being due to activity against the receptors that the assays 
are designed to test. The follo\ving scheme was used to filter out these non-selective, cell-
stress I cytotoxicity-related assay hits. For chemicals \Vith t\vo or 1nore positive responses 
in cytotoxicity assays, \Ve calculated the median logAC50(cytotox) and the MAD of the 
logAC50(cytotox) hits. Next, \Ve calculated the rnedian of the .MAD of the 
logAC50(cytotox) distributions across all chemicals to define the global cytotoxicity 
MAD. A new value {the Z-score) was then assigned to each in vitro assay hit: 
Z(chentical,assay):::: 
log A C50( chemical, assay) -111edia11[log A C50( chen1ical, cytotoxicity )] (!) 
MADgtoba1 
If fe,ver than 2 cytotoxicity assays are hit, the median cytotoxicity concentration is 
arbitrarily set to 1000 CM, which sin1ply sets all Z-values tbr assay hits to a value >3. A 
hit \Vith a large value of Z occurs at concentrations significantly belo\V \vhere cytotoxicity 
is occurring. This hit is more likely due to target-selective 1nechanis1n biological activity .. 
The global cytotoxicity MAD is 0.26 log units. 
Structure of the Network Model: Figure 1 is a graphical representation of the network 
n1odel used to evaluate the integrated in vitro assay responses. The model was based on 
the series of molecular events that typically occur in a nuclear receptor-1nediated 
response (Mangelsdorf, Thummel et al. 1995, Gronemeyer, Gustafsson et al. 2004). The 
process starts with the interaction of a che1nical with an ER (Receptor node Rl). For 
exan1ple, an ER agonist \Vil! cause the receptors to din1erize (node NI), translocate to the 
nucleus and recn1it co-factors to fonn the complete active transcription factor co1nplex 
(TF) (node N2). This TF binds to the chromatin DNA (node N3), initiates transcription of 
mRNA (node N4) and subsequent translation to protein (node N5). For ER agonist 
activity, one do\vnstrean1 consequence can be cell proliferation (node N6). Note that the 
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temporal order of these processes is not necessarily as depicted here. Each of these 
processes (\vith the exception of cofactor recniihnent) was measured in the current 
collection of 18 b1 vitro assays (represented in the figure as \vhite stars). Table 1 (see 
Methods) provides the assay ID (Al-A18) to 1natch the associated in vitro assay on 
Figure 1 and a brief assay description. More detail is provided in Supplemental File SI 
Appendix L The ER path\vay is sho\vn in f\vo n1odes: agonist (blue) and antagonist (red). 
The model assumes that a chemical interacting \Vith the ER will bind in one or both of the 
agonist or antagonist confonnations and in tun1, trigger activity in the appropriate 
path\vay. Note that the model allows for the prediction of mixed agonistfantagonist 
activity. 
In addition to ER-n1ediated effects, each individual in vitro assay is subject to 
processes that can lead to non-specific activity, independent of the ER path\vay node that 
it is supposed to 1neasure. The assay interference path\vays were 1nodeled as alternate 
"pseudo-receptors" (gray arro\v nodes). The details of the process connecting the 
theoretical pseudo-receptors to the assays were sin1plified to a single connection because, 
in general, we do not know the intern1ediate details of these processes or even the identity 
of the pseudo-receptors. Note that the pseudo-receptors are conceptualized here as 
surrogates for generic processes such as cytotoxicity that can lead to non-ER mediated 
assay activity. It is possible to describe many potential alten1ative assay interference 
pathways, but in general, the current data are not sufficient to distinguish bet\veen 
alten1ate 1nodels. Pseudo-receptors are then assigned to each group of assays (technology 
group) and to each assay individually. Only a single example of an assay-specific pseudo-
receptor is sho\vn in Figure 1, but all assays (\vith the exception of Al6/R8 where the 
assay and the receptor are identical) have a corresponding pseudo.receptor. The botton1 
panel of Figure l sho\vs the pattern of activity one \Vould expect if specific receptors are 
activated, in this case Rl, R2 and R6. 
1lfathe11iatical Representation of the Nehvork 1\fodel: The computational model assumes 
that the value (the efficacy, A) returned by an assay at a given concentration is a linear 
surn of the contributions fron1 the receptors that it measures, i.e. it is a simple linear 
additive model: 
(2) 
\vhere the elements of the F 1natrix are 1 if there is a connection between a receptorj and 
an assay i and 0 othenvise. The index i goes over all assays and the indexj goes over all 
receptors. This holds for direct connections, where a receptor is directly linked to an 
assay in Figure 1, and for indirect connections, \Vhere a receptor is linked through one or 
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n1ore inten1al nodes, designated by the circles in Figure 1. Therefore, the 1nodel assun1es 
lossless transmission of signals from the receptor through the internal nodes to the assays. 
The goal is then to find a set of R1 values that minimize the difference behveen the 
predicted assay values ( A/1'<..J) and the measured ones ( A;"""1.)) for each chemical and 
concentration. A,f"'"d is calculated using the fonvard model (Equation 2). For each 
chemical-concentration pair, a constrained least-squares 1nini1nization approach is used 
\vhere the function being miniinized is: 
N,_,,,_. 
£ 2 = L (Ar"' -Ar"J.! r + penalty(R) 
i=l 
(3) 
\vhere A,~ must satisfy the constraints: 
AP"d E [O I] I ' , (4) 
It is possible to assign weights to the assays in the sum of Equation 3, but in practice, this 
did not change the results in any qualitative \Vay, and introduced a nun1ber of additional 
free paratneters into the model. The tenn penalty(R) penalizes solutions that predict that 
many receptors are being simultaneously activated by the chemical. It is given by 
x10 
penalty(R) =a 10 10 x +0.5 (5) 
\Vhere x = '~~-" "TJ. L1=I -'"i 
This penalty term helps stabilize the solutions and enforces a reasonable physical 
assun1ption about chemical promiscuity, e.g., it is unlikely that n1any or tnost chemicals 
\vill selectively interact \Vith a number of dissimilar n1olecular targets through 11011-
covalent binding. Note that this problem is underdetennined because there are more 
receptors than assays, and so does not have a unique solution. "\Ve investigated two other 
commonly used penalty terms, RIDGE(Hoerl and Kennard 1970) and LASSO (Tibshirani 
1996) as described in Supplemental File Sl, Appendix 2. The penalty tenn in Equation 5 
(called THRESHOLD) \Vas selected because it best enforced the physical constraint, and 
because results \Vere less sensitive to the exact value of a. For most results, we use an 
intern1ediate value of a=l, but the final data files additionally give selected values for 
a=0.01 and a=lOO. The penalized least-squares solution to Equation 3 is carried out 
using the R-language function optbn in package stats (Thaka and Gentlernan 1996) , with 
method= L-BFGS-B and the constraints in Equation 4. \Vhen solving the equations, \VC 
start from the lo\V concentration end where the expected activity is zero and i1se this as 
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the initial condition for all receptors in the model. For subsequent concentrations, we then 
use the output values for the previous concentration as the initial values for the current 
one. The n1odel results in a response value (bet\veen 0 and l) for each receptor at each 
concentration. The activity for each receptor is sumn1arized as an area under the curve 
(AUC), which is the quadrature integral across the concentration range: 
I N<'"~C 
AUC(R1) = N'"' ~ sig11(slope)xR1(co11c,) . (6) 
The factor sign(slope) is included to handle cases \Vhere one of the assays or sets of 
assays is active at significantly lo\ver concentrations than the remaining assays. The 
corresponding receptor curve \Vill then rise and subsequently fall, and this AUC needs to 
be discounted. Finally, AUC values are scaled so that AUC(agonist)=l for l?a-
Ethinylestradiol, \Vhich is the positive reference con1pound for all agonist assays. 
AUC(Rl/agonist) and AUC(R2/antagonist) (or subsequently 
AUC{agonist)/AUC(antagonist)) is the terminology used to describe the activity in the 
agonist and antagonist modes, respectively. AUC(Ri;i>2) describes activity in one of the 
other pseudo-receptors 3-9. AUC(Ai) describes the AUC value for one of the single-
assay pseudo-receptors. 
One challenge with this modeling approach is how to interpret the AUC values. 
For a pure ER agonist (no activity in any of the pseudo-receptors), the AUC(agonist) vs. 
concentration curve closely resembles the concentration-response profile for any of the 
assays, with activity going fro111 0 to I with an AC50-like value close to that observed in 
the assays. For mixed cases, the concentration-response curves may be more complex 
than a Hill curve and \Vill have a maxinlltm efficacy of less than 1. Qualitatively, \Ve 
interpret these AUC values as concentration-specific probabilities that the chemical is 
interacting with the corresponding (pseudo) receptor. One final set of quantities 
calculated are the "median-AC50" values. These are the median values of the log-AC50 
for assays active for that che111ical. 
Results 
Obse1Ted Correlation A111011g 111 Vitro Assays Fro111 tlie Sa111e Technology: T\VO-
dirnensional hierarchical clustering \Vas perfonned on the potencies (log AC50 values) of 
the 18 ER-related in vitro assays (Figure 2). Strong clustering by technology I pseudo-
receptor \Vas observed. The hypothesis \Ve tested in this paper is that assay 
interference exists, and is at least somewhat driven by specific chemical-technology 
activity that is independent of ER-ligand binding. In a clustering analysis like this, if 
the clusters largely line up \Vith technologies, then that is at least supportive of our 
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hypothesis. Note that the one exception to this clustering is R7 (the Tox21 agonist 
assays), \Vhich \Vere grouped because they \Vere run in the same lab rather than 
because they \Vere the same technology (they have different readouts, cell lines). 
This plot suggests that some fraction of positive assay responses are caused by 
technology-specific assay interference rather than ER receptor-n1ediated activity. Other 
chemicals sho\ved activity across a broad range of ER-related in vitro assays. 
Nehvork ftfodeliug of Ju Vitro Assay Activity: Figure 3 illustrates co1nmon types of 
assay activity and model behavior represented by prototype chemicals. For example, 
bisphenol A (BPA) sho\VS a clear concentration-response in agonist activity (right-hand 
panel, blue curve). Ho\vever, there is also activity in the R6 pseudo-receptor 
(corresponding to the transactivation assays) that rises at lo\v concentrations and then 
drops. The corresponding in vitro assays shO\V activity at lower concentrations than the 
others, but at high concentrations, substantial evidence points toward agonist activity. 
Note that BPA also has activity in one of the antagonist assays (upper left panel, Al7, 
gold line), consistent with known SERM activity at high concentrations (Nagel, 
Hagelbarger et al. 2001). 4-hydroxytamoxifen, a reference antagonist, sho\VS clear 
antagonist activity. Alpha-cyclodextrin sho\vs strong activity only in the three cell-free 
binding assays, resulting in a strong assay interference signal in the R3 pseudo-receptor. 
This is likely because this chemical interferes with the radioligand assay by binding to the 
radioligand. This 1nolecule is kno\vn to bind hydrophobic 1nolecules such as fhtty acids 
and cholesterol (Christian, Haynes et al. 1997). The nloSt frequent case (not sho\Vll here, 
762 out of 1812, 42%) is one in which there is no activity in any assay. Notice that 58% 
of chen1icals have at least some activity in at least one assay. A priori, one '\'.'ould not 
expect this high a fraction of tnie positives in a diverse chetnical library, so significant 
assay interference I false-positive activity is likely to exist. TI1e data for the con1plete set 
of chemicals are given in Supple1nental Files S2 (tabular) and S3 (plots corresponding to 
Figure 3). Data is also available through the EDSP21 dashboard: 
http://actor.epa.gov/edsp2l and the ToxCast data web site: 
http://epa.gov/ncct/toxcast/data.html. Table 3 provides a longer list of positive chemicals 
across potencies and stnrctural classes. 
Reference Clte111icals: The AUC values for the ER reference chetnicals are plotted in 
Figure 4. For the positive agonist chemicals, all but diethylhexyl phthalate (DEHP) and 
dicofol have non-zero AUC(agonist) values. DEHP is inactive in all assays, but dicofol is 
active in 3 of the 6 diinerization assays near the top of the tested concentration range, 
\vhich results in a small but non-zero AUC(R4) value of 0.02. These t\vo chetnicals are 
in the "Very \Veak" class, so they are potentially active only at concentrations above 
\vhere the current assays have been tested for tnost or all assays (100 CM). The 
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AUC( agonist) values for the other positive chemicals are ordered approxhnately with the 
expected potency class. All of the negative agonist reference chen1icals sho\ved 
AUC(agonist) values of zero. 
All four of the positive antagonist reference che1nicals are positive \vith large 
AUC(antagonist) values. Three negative antagonist reference chen1icals yield non-zero 
AUC(antagonist), but all are <0.05. Most of the negative antagonist reference che1nicals 
are positive references for the agonist mode, and they appropriately yield a high 
AUC(agonist) value. A specific example is dibutyl phthalate, \Vhich is defined in the 
OECD reference list as a very \Veak positive agonist and a negative antagonist. Our data 
sho\vs very \veak activity in both modes, but all activity occurs in the cytotoxicity region 
(see the inset in the figure). Therefore, the activity in the antagonist assays leading to the 
non-zero AUC(antagonist) may be driven by false-positive loss of signal due to 
cytotoxicity. In general, \Ve see that the positive reference che1nicals, \Vith the exception 
of some that are very \Veak, are classified as having the appropriate activity class (i.e., 
agonist or antagonist). Negative reference che1nicals either have no activity in any assay 
or are classed as being active in only one of the pseudo-receptor channels \Vith scores 
higher than for the agonist or antagonist receptors. Supple1nental File 84 provide the 
agonist and antagonist mode AUC values for the reference chemicals and plots of the 
assay and receptor concentration-response profiles, respectively. 
Activity Classifications of the Conu11e1·cial and E1n•iro11111e11tal Clle111icals: Figure 5 
summarizes the results of the modeling eftbrt over the 1812 chemicals. ln the idealized 
case where all assays are activated (either for the agonist or antagonist mode) at the sarne 
concentration, and reach 100% efficacy, the relation behveen the n1edian-AC50 (\vhich 
\Vould be the common AC50 for all assays) and AUC would be linear. However, in the 
more common case \Vhere the assay AC50s are spread out, the agonist I antagonist curve 
tends to rise sooner than the nledian of the assays (See Figure 3 for BPA comparing the 
blue agonist curve \Vith the assays ACSO median, the green vertical line). The dashed 
line is the best fit from a linear regression between AUC and log(rninimum-AC50) for 
chemicals \Vith AUC>0.1. The horizontal line at AUC=O. l provides a qualitative break 
behveen chemicals following the linear AC50 vs. AUC trend and those sho\ving lo\v 
potency in one or a few assays. 
Chemicals fall into one of several general groups. The first are those lying along 
the dashed line, which is the expected behavior for true actives. \Ve have labeled the most 
potent non-reference chemicals, those with AUC>0.4 (chemicals 1-10). Fulvestrant, 
equilin, estriol, clomiphene citrate, and mestranol are all steroid pharmaceuticals that are 
designed to target ER (\Vishart, Knox et al. 2008). Bisphenol AF is a close analog of 
bisphenol A, one of the reference agonist chernicals. Zearalenone is a 1nycotoxin \Vith 
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ki10\vn estrogenic activity (Le Guevel and Pakdel 2001, Higa~Nishiya1na, Takahashi-
Ando et al. 2005). HPTE is a degradate of the pesticide methoxychlor and is a known 
environmental estrogen (Miller, Gupta et al. 2006). Norethindrone is a progesterone 
derivative. l 7beta-trenbolone is synthetic androgen. Both of these steroids appear to be 
\veakly active against ER relative to their activity in their native receptor. Therefore, none 
of the most potent set of actives is novel. It should be noted that norethindrone, as \Vi th 
other steroid chemicals, could be contarninated with a low level of a 1nore potent 
derivative, which for this chemical \Vould be the estrogen mestranol. \Ve have analytical 
QC on norethindrone (data not shown), which sho\vs all san1ples are at least 90% pure. 
Ho\vever, given that inestranol is approximately 2 orders of rnagnitude 1nore potent, it 
\vould only require a I% contamination level to exhibit the observed activity. 
A second interesting set of chemicals are those labeled in cyan in Figure 5 
(chemicals 11-13). These have low but significant AUC values (0.1~0.2) but have at least 
one very potent AC50 value. The tnost potent of these is 4-androstene-3,17-dione, a 
potent androgen. The assay plot for this chemical is shown as an inset in Figure 5. The 
most potent assays are the ATG transactivation assays. This assay platform has t\vo 
interesting features, first that it is n1n in l-IepG2 cells with so1ne metabolic activity, and 
second, that it is. highly multiplexed, including having androgen receptor readouts 
simultaneous with those for the estrogen receptor. So, t\vo possibilities exist for the 
potent activity of this androgen - there could be inetabolic activation, leading to real 
ER activity, or there could be assay technology crosstalk. Understanding this behavior is 
the subject of ongoing research. Melengestrol acetate is a progestin, and is most potent in 
the ACEA cell proliferation assay. The cells used in this assay (T47D) are kno\vn to be 
sensitive to progestins and glucocorticoids (Chan, Klock et al. 1989). 
3,3'-Dimethylbenzidine dihydrochloride, an intermediate in the production of dyes, is 
active in the 3 cell-free radioligand binding assays, indicating its potential to disn1pt the 
protein in these assays, potentially through protein denaturation. 
A final set of chemicals are those with some \veak activity in one or inore of the 
assays. There are further chemicals \vith AUC(agonist) in the range of values seen with 
the weak and very \Veak reference chemicals (green triangles, lower right of figure), and 
these \Vould be \\'Orth additional investigation, although with a lo\ver priority than those 
che1nicals that are 1nore potent. Note that there is greater uncertainty about activity for 
chemicals \vhere the "true" activity approaches the upper lin1it of testing (100 r:M) 
because of the large spread in AC50 values across the assays. Finally, there are a set of 
chemicals \Vith very lo\V median~AC50s, but low or zero AUC(agonist/antagonist) (black 
points running along the bottom middle). These che1nicals are very potent in one assay or 
technology, and are the typical chemicals causing assay interference. 
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One goal of this study \Vas to determine whether a chemical interacts \vith ER 
based on data fro1n in vitro assay \vhich is subject to noise and assay interference. Table 2 
gives the counts of chemicals for each of the receptors or pseudo-receptors \Vi th at least 
one che1nical having an AUC>0.2, over selected ranges. For the agonists and antagonists, 
one can see that the number of chemicals in these potency categories shifts as a function 
of the penalty tenn strength a (see Equation 5). 
Understanding all of the causes of assay interference (and hence pseudo-receptor 
activity) is beyond the scope of this study, but we analyzed t\vo inajor factors that appear 
to play a role. These factors include non-nom1al baseline variability and cytotoxicity or 
cell-stress-induced non-specific activity. hl the assay data processing pipeline (see 
Methods), baseline variability is assun1ed to be approxin1ately normally distributed, and 
to be due to noise processes. However, other processes can cause baseline shifts, for 
instance uncorrected edge effects on a microtiter plate. Assay data processing attempts to 
correct for these types of effects, but in a high-throughput automated system, some issues 
\Vill remain. A second potential cause of assay interference is cell-stress or cytotoxicity 
related non-selective activity. \Vith in vitro assays, one often observes false activity in 
many assays at concentrations near cytotoxicity. The Z-score (see methods) is used to 
quantify the relative proxi1nity of an assay AC50 to the cytotoxicity region. Qualitatively, 
Z<3 tnay be associated with cytotoxicity, while Z ~ 3 is not. For n1ost assays, we observe 
a bimodal distribution of Z-scores with a minimum at ...-3. An example of the Z-score 
distribution is sho\vn in Figure 6 for ATG_ERa_TRANS_up (assay A12). 
For subsequent analyses, we examined chemical activity after filtering for 
likely non-ER activity using the maxin1um efficacy (Top or T) and cytotoxiclty (i.e., z-
score). For each chemical, the nledian T and Z-scores were calculated for the 
corresponding assays, and cheinicals were removed with T<50% or Z<3. A total of 165 
chemicals passed this filter. The chemicals filtered out \Vere typically those with lo\v 
AUC values (active only at high concentrations). Figure 7 sho\vs the fraction of 
cheinicals re1naining after the filtering for receptors or pseudo-receptors with more than 5 
hits and with AUC>0.1 before filtering. For illustration, only multi-assay pseudo-
reccptors are shown. One can see that the IO\V AUC bins lose the most number of 
chemicals. Pseudo-receptor R9 loses the largest fraction of chemicals in all bins, likely 
because the loss-of-signal antagonist assays 1naking up R9 are the inost subject to being 
confounded by cytotoxicity (Huang, Sakamun1 et al. 2014). This is in contrast to R3, 
made up of the cell-free radioligand binding assays, which lose the smallest fraction of 
chemicals in the intennediate AUC bins, likely because these assays are less sensitive to 
the cytotoxicity processes. Finally, note that a number of agonist and antagonist 
chemicals in the low and intermediate AUC bins are also lost. These are chemicals that 
are active in 1nany ER assays, and include some of known \Veak estrogens (linear 
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nonylphenol is an cxatnple), but \vhosc activity all occurs in the cytotoxicity region. \Ve 
would argue that, \Vhilc these che1nicals n1ay be tndy cstrogenic, they are of n1ore 
concern fron1 their cytotoxicity than as estrogens. 
A total of 72 chemicals have an AUC(agonist) or A UC( antagonist) >0.1, 111edian-
Z-score >3, and 1nedian-T >50%, These arc listed, along \Vith a variety of annotations in 
Table 3. Many of these che1nicals fall into t\vo 1nain structural classes \Vith known 
estrogenic activity - steroids (16, 22%), and phenol-containing eo1npounds (41, 57%). 
Pham1aceuticals are the most \videly represented use class (28, 39%). Other use classes 
include antioxidants, detergents/surfactants, pesticides, plastics and other industrial 
reagents and UV absorbers. Another interesting class arc che1nicals that are found in 
foods, including the natural phytoestrogen flavones genistein, daidzein, biochanin A, 
apigenin, kaempferol and chrysin; and the flavor I fragrance ingredient 4-(2-n1ethylbutan-
2-yl)cyclohcxanol (also kno\vn as 4-tert-atnylcyclohexanol), which is a perfurne 
ingredient. 
Discussion 
\Ve have developed a computational approach to distinguish tn1c ER reccptor-
rnediated agonist and antagonist activity frotn false positive activity often related, \Ve 
postulate, to assay interference. The pri1nary driver of this application is the need to 
screen thousands of n1an-n1ade chernicals found in the environ1nent for their potential to 
interact \Vith the estrogen receptor. Current in vivo n1cthods used for chernical safety 
testing are too slo\v and resource intensive to screen a set of che1nicals of this n1agnitude. 
The present incthod ranked large 11un1bcrs of chen1icals based on potential ER path\vay 
activity in a inanner that is useful for setting priorities for further screening or testing. 
The n1ethod described here uses a network 1nodel to integrate concentration-
rcsponse profiles for a collection of 18 in vitro assays probing different molecular 
processes in the ER patlnvay. The n1odel assigns scores for hue agonist and antagonist 
activity as \\'ell as scores representing non-receptor mediated effects. Model scores are 
co1nbined \Vith a 1neasure of relative efficacy and cytotoxicity-related assay activity. 
These results indicate \Vhether the activity of a chen1ical is most likely ER mediated, or 
related to either assay- or technology-specific assay interference. Model results 
demonstrated that the inethod \\'orks \Yell for a set of reference che1nicals by correctly 
identifying agonist, antagonist and inactive co1npounds \Vith high sensitivity and 
specificity. The model agonist score [AUC(agonist)] is also correlated \vith the expected 
potency class of the active reference che1nicals. 
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Additionally, this study allowed us to probe 1nechanis1ns behind assay 
interference. The existence of this phenomenon is \Vell known in the phannaceutical 
industry, and son1c models to identify interfering chemicals are available (Baell and 
IIollo\vay 2010, Bn1ns and \Vatson 2012). However, \Ve believe that the types of 
interference one sees may indicate important aspects of the underlying biology triggered 
by these chemicals, although typically only at high concentrations. \Ve have 
de1nonstrated here that a fraction of pseudo-receptor activity is associated with 
cytotoxicity, but the phenomenon of cytotoxicity is not uniform. In particular, Figure 7 
shows that the chemicals \vith lo\ver support for activity against any of the receptors or 
pseudo-receptors (as measured by AUC values) are the ones most likely to have assay 
activity occurring only in the cytotoxicity region. In the ToxCast assay portfolio, a total 
of35 cytotoxicity assays are n1n in n1ultiple cell types (cell lines and prhnary cells), and 
different types of readouts (primarily measuring decrease in viable cell count, ATP levels 
or decrease in rate of cell proliferation). \Ve observed (data not shown) that n1any 
chemicals will trigger only one class of the cytotoxicity assays in the cell-stress J 
cytotoxicity region (e.g., only the cell-line-based assays, or only the reduced proliferation 
assays), indicating the potential for a specific mechanism for cytotoxicity. The ToxCast 
assay portfolio also contains a collection of cell stress assays (e.g., oxidative stress, 
endoplasmic reticulum stress, tnitochondrial disn1ption). \Ve are currently studying ho\v 
to combine patten1s of assay interference, cell stress and cytotoxicity with the aim of 
better understanding how chemicals perturb cells at high concentrations. Understanding 
these effects 1nay also help interpret the results of typical high-dose animal toxicity 
studies as many of these effects are dose-dependent. 
The goal of this model is to identify potential estrogen-related hazards, i.e. to 
determine \vhether a chetnical is likely to interact \Vith the estrogen receptor. Equally 
important to carrying out a full risk assessment are the need to understand exposure (to 
single chemicals or 1nixtures), phannacokinetics, in vii·o adaptation, etc. To this end, we 
are also developing high-throughput quantitative estitnations of phannacokinetics 
(Rotroff, Wet1nore ct al. 2010, Wetrnore, \Vambaugh et al. 2012, Tho111as, Philbert et al. 
2013, Wetmore, \Vambaugh ct al. 2013, Wambaugh, \Vetmore et al. 2015) and chen1ical 
exposure (\Varnbaugh, Setzer et al. 2013, \Vambnugh, \Vang et al. 2014). In combination, 
these will provide the capability to develop risk-based priorities for targeted testing 
within the frarnework of high-throughput risk assessn1ent (Judson, Kavlock et al. 2011 ). 
In parallel, we are have also perfonned a direct comparison of the current model 
with data from guideline uterotrophic studies [Kleinstreuer et al. subtnitted](Bro\vne, 
Judson et al. 2015). The result of this comparison is that the current ER model results are 
predictive of in vivo uterotrophic assay results. In particular, for che111icals nn1 in at least 
2 uterotrophic, guideline-like studies, the sensitivity and specificity of the ER inodel were 
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97% and 89% respectively, once ER-1nodel-a1nbiguous results were excluded, i.e. 
cheinicals with 0.0 I <AUC(agonist)<0.1. If all guideline-like uterotrophic data from the 
literah1re is included (incorporating che1nicals for \vhich only a single assay \Vas 11111), the 
sensitivity and specificity drop to 86% and 90% respectively. These values need to be 
compared with the observed discrepancies between guideline-like uterotrophic assays n1n 
for the saine chetnical in different laboratories. Kleinstreuer ct al. docuinented that 26% 
of che1nicals had discrepant results, i.e. at least one positive and one negative result. So in 
summary, \Ve believe that the agonist 1nodel results can serve as a reliable indicator of ER 
activity both in vitro and in vivo, \vith sensitivity and specificity comparable to that 
provided by the guideline uterotrophic assay. Chernicals \Vith AUC(agonist)2:0.l are 
likely in vivo active; those \vith AUC(agonist)<0.01 are likely in vivo inactive; and those 
in the intennediate region are mnbiguous, and 1nay require further testing to n1ake a 
definitive call. The agonist and antagonist AUC scores, in addition to all assay data, are 
available at the EDSp21 dashboard: http://epa.gov/ncct/toxcast/data.htn1l and 
htto://actor.epa.gov/edsp21. 
In addition, the n1ethod described here is general enough to apply to any pathway 
for which 1nultiple assays are available that probe different points in a pathway using 
1nultip1e technologies. \Ve currently have equivalent data sets to the one described here 
for the androgen receptor, steroidogenesis, and the peroxisome proliferator activating 
receptor (PPAR) pathways. \Ve are also adding physico-chetnical properties and other 
stn1ctural features to try and develop ntles to be used in designing safer alten1atives to 
currently widely used chemicals. The estrogen receptor context is helpful in this broad 
area because we can better assess what is tn1e receptor-1nediated activity as opposed to 
assay interference. \Ve can likely apply assay interference infonnation for specific 
chemicals derived fro1n this ER study to the behavior of those chetnicals in other 
path\vays, for which \Ve do not have this large assay coverage. 
Supplementary Data Description: 
Four supple1nental files are provided: 
SI SUPPLEMENTAL ER pathway model 2015-04-08.docx: This provides further 
details on the experimental protocols (in vitro assays), and infonnation on sensitivity 
analysis for the model 
S2 ER SuperMatrix 20 t 5-03-24.xlsx: Spreadsheet with all input and output data and 
n1odel parameters the 1800 chen1icals 
S3 AUC plots for all chemicals 2015-03-24 THRESHOLD l.pdf: plots for all 
chemicals sin1ilar to the exan1ples shown in Figure 3. 
S4 AUC plots for reference che1nicals 2015-03-24 THRESHOLD l.pdf: plots for 
the ER reference chemicals sirnilar to the exainples sho\vn in Figure 3. 
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Additionally, the software used to n1n the model and all input and output data will be 
provided as a zip file on the authors' \veb site: http://epa.gov/ncct/toxcast/data.htn1l. 
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Rgure Legends: 
Figure 1: (A) Graphical representatio11 of the computational network used in the in vitro 
analysis of the ER pathway across assays and technology plntfonns. Colored arro\v nodes 
represent "receptors" with \Vhich a chemical can directly interact. Colored circles 
represent intennediate biological processes that are not directly observable. \Vhite stars 
represent the in vitro assays that measure activity at the biological nodes. Arro\vs 
represent transfer of infonnation. Gray arrow nodes are the pseudo-receptors. Each in 
vitro assay (\Vith the exception of Al6) has an assay-specific pseudo-receptor, but only a 
single example is explicitly shown, for assay At. (B) Patten1s of assays that \vould be 
activated when specific receptors are activated by the chemical, in particular Rl, R2 and 
R6. The activating che1nical in its receptor are circled in pink, and the activated assays 
and the patlnvays to then1 are also highlighted in pink. 
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Figure 2: Two-\vay hierarchical clustering of che1nical activity across the 18 in vitro 
assays used to test for ER activity. Assays and technologies arc aligned across the x-axis, 
\Vhere the "A" and "R'' values refer to the assay and receptors/pseudo-receptors frorn 
Figure 1 and Table l.Che1nicals are aligned along the y-axis. The heattnap sho,vs -
loglO(AC50) values for all assays and all chemicals with at least one assay hit. Darker 
red indicates 1nore potent activity (lo,ver ACSO), while white represents inactive 
chc1nical-assay pairs. Note that the assays cluster by technology I pseudo-receptor. 
Figure 3: Results of the model for three prototype chemicals. For each chemical, the Ieft-
hand panel sho,vs the synthetic concentration-response data for the 18 assays, colored by 
assay groups defined in the legend. The right-hand panel sho,vs the corresponding 
n1agnitude of the modeled receptor responses. The agonist receptor (RI) is designated by 
blue, the antagonist receptor (R2) by red and the other pseudo-receptors are colored as 
indicated in the legend. AUC values for the agonist (RI) and antagonist (R2) receptors 
are provided belo\v the che1nical naine. For chetnicals with cell-stress I cytotoxicity 
activity (2 or 1nore cytotoxicity hits, see Methods), the cell-stress I cytotoxicity center is 
indicated by a vertical red line, and the ceil-stress I cytotoxicity region (starting 3 cell-
stress I cytotoxicity MAD below the cell-stress I cytotoxicity center) is indicated by the 
gray shaded region. A green horizontal bar indicates the 111edian-AC50 of the active 
assays. Sin1ilar plots for all chen1icals are given in Supplemental File S3. 
Figure 4: Plots showing activity of the agonist (top) and antagonist (bottotn) reference 
che1nicals. Chemicals that are intended to be positive are indicated by green circles, \Vhile 
those intended to be inactive are indicated by red circles. For the agonists, the expected 
potency range is also indicated (middle colunu1). For chetnicals 'vith one or 1nore pseudo-
rcceptor AUC values greater than zero, the value is indicated by an X, and the pseudo-
rcceptor nmne is indicated. The inset sho\VS the assay curves for dibutyl phthalate, as 
described in the text (colored based on Figure 3). 
Figure 5: Plot of the n1axirnurn AUC vs. n1inin1un1-AC50 values. Each point is a single 
che1nical that was active in at least one assay. The AUC value given is the 1naxin1um of 
the AUC(agonist) and AUC(antagonist) values for the chemical. The dashed line is the 
best-fit for AUC(agonist) values >O. I. Cheinicals arc labeled in order: black circle, at 
least one AUC>O.l; green up-triangle, positive agonist reference chernical; green down-
triangle, positive antagonist reference che1nical; red diarnond, negative reference 
che1nical; cyan circle, exarnple chernicals with AUC significantly belo\V the fitted line 
but above 0.1. The vertical line at 100 CM indicates the highest concentration tested, 
while the horizontal line at AUC=0.1 indicates an approxi111atc threshold between 
chemicals with clear agonist I antagonist activity and those that arc potentially active 
24 
through interference processes. The inset sho\vs graphs of assay activity for 4-androstene-
3,17-dione (colored based on Figure 3). 
Figure 6: Histogra1n ofZ-scorcs for the assay ATG_ERa_TRANS_up. The Z-score is 
defined as the distance between the median cytotoxicity concentration and a chemical's 
ACSO in this assay, in units of global cytotoxicity MAD, for all chemicals active in this 
assay. One can see a bi1nodal distribution \Vith one peak at zero (marked with a heavy red 
line) and another with a peak near 6. \Ve hypothesize that chemicals active in the lo\v-Z 
region are more likely to be false positives and less likely to be estrogenic than those 
active in the high-Z region. 
Figure 7: Bar chart showing the fraction of chemicals remaining for each of the multi-
assay receptors I pseudo-receptors after filtering for efficacy (T) and cytotoxicity (Z-
score). The receptors were lin1ited to those with 5 or 1nore chemicals \Vith AUC>0.1 
from Table 2. If there were no chemicals for a pseudo-receptor in a given AUC bin, a 
sn1all negative bar is shown. The legend indicates AUC ranges corresponding to Table 2. 
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Tables 
Table 1: Su1nn1ary of the in vitro assays used with their ID mapping to the model in Figure 1. Fu1iher details are p 
Supplemental File Sl, Appendix 1. NVS=Novascreen; OT=Odyssey Thera; ATG=:Attagene; Tox2l==assays run by 
Institutes of Health's National Center for Advancing Translational Sciences (NCATS) as part of the Federal Tox2l 
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Table 2: Counts of chemicals for each receptor/pseudo-receptor as a function of AUC value. Only receptors or pse 
at least one chen1ical with AUC>0.2 are listed. Counts for the agonist and fintagonist modes as a function of a ar 
that for the pseudo receptors, all values use a=l. 
Receptor 0.1 to 0.2 0.2 to 0.5 0.5 to 1 
AUC(Agonist) a~o.o 1 22 37 12 
AUC(Agonist) a~l 36 42 14 
AUC(Agonist) a~100 51 49 16 
AUC(Antagonist) a~0.01 4 4 4 
AUC(Antagonist a=l 9 4 5 
AUC(Antagonist) a~lOO 10 8 5 
AUC(R3) 3 2 0 
AUC(R6) 36 7 0 
AUC(R7) 0 0 1 
AUC(R8) 14 15 2 
AUC(R9) 21 4 0 
AUC(Al) 0 1 1 
AUC(A2) 4 1 0 
AUC(A3) 12 7 0 
AUC(A12) 17 2 0 
AUC(A\3) 32 9 0 
AUC(Al5) 30 5 0 
AUC(A17) 29 6 0 
AUC(A18) 7 6 0 
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Table 3: The n1ost potent 72 agonist and antagonist chetnicals out of the 1812 tested. To be included in the list, 
or AUC(antagonist) had to exceed 0.1, the 1nedian Thad to be >50%, and the 1nedian Z had to be greater than 3. 
are set to zero. Chemicals arc ordered by decreasing value of AUC(Rl). 
CASRN Name E).:ample Use Structure Cate-gory AUC AUC 
(Agonlst) (Anlag 
57-91-0 I7alpha-Estradiol Phannaceutie-al steroid E 1.06 0 
57-63-6 l 7alpha-Ethinylestradiol Pham1aceutklll steroid E l 0 
84-16-2 mc;;o-Hexestrol Pharmaceutical phenol-phenol [CCJ 0.99 0 
56-53-l Diethybtilbestro\ Pharmaceutical phenol-phenol [CCJ 0.94 0.01 
50-28-2 17bcla-fulradiol Pharmaceutical steroid E 0.94 0.02 
474-86-2 Equilin Phannaccutical steroid E 0.82 0 
53-16-1 Estrone Pbamtaccutical steroidE 0.81 0.002 
50-27-1 Estriol Pharmaceutical steroid E 0.79 0.01 
72-33-3 Mcstranol Phamtaccutical steroidE 0.74 0 
17924-92-4 Zearalenone Myco!oxi11 carboxylic add ketone 0.71 0 
2971-36--0 HPTE Pesticide de gradate phenol-phenol [CJ halide 0.57 O.ll4 
1478-61-1 Bhpheno!AF Plastics phenol-phenol [q halide 0.55 0 
446-72-0 Gcnistci11 Natural product genistcin·like 0.54 0 
77-40-7 Bisphenol B Plastics phenol-phenol [C] 0.49 0.002 
80-05-7 BisphenolA Plastics phenol-phenol [CJ 0.45 0 
486-66-8 Daidzcin Flavone gcnlstein-like 0.44 0 
84852-15-3 4-Nonylphenol, branched Detergent ingredient phenol alkyl 0.44 0 
105624-86-0 5HPP-33 Phannaceutical thalidomide-like 0.42 0 
104-43-8 4-Dodecylphenol Industrial intemlCdiate phenol all..·yl 0.41 0 
521-18-6 5alpha-Dihydrotestostcronc Phannaceu!kal steroid A 0.4 0 
131-55-5 2 ;2.' ,4,4' -Tetrahydroxybenzophenone UV-absorber phenol-phenol [CO] 0.40 0 
30 
797-63-7 Norgestrel Phattl'laeeutical steroid P 0.39 0 
140-66-9 4-(l ,l,3,3-Tetramethylbutyl)phenol Chcmieal intermediate phenol alkyl 0.39 0 
27193-86-8 Dodecylphenol Chemical phenol alkyl 0.39 0 
re.;:ictant/solvent 
57..S5-2 Testosterone propionate Pharmaceutical steroid A 0.39 0 
789-02-6 o,p'-DDT Insecticide phenyl-phenyl [C] chloro 0.39 0 
5&-72--0 Triphenylethykne Chemical l\."'<!etant triphCT1yl (CJ 0.38 0 
599-64-4 4-Cumylphenol Industrial intermediate phenol-phenyl [C] 0.38 0 
5153-25-3 2-Ethylhexylparoben Microbicide paroben 0.37 0 
53-43--0 Dehydroepiandrosterone Phannaeeutical steroid A 0.37 0 
491-80-5 Biochanin A Fiavone genistein-like 0.36 0 
68-96-2 l 7alpha-Hydroxyprogestecone Phannaceutical steroid P 0.34 0 
27955-94-8 4,4',4-Ethane· l, l, 1-triyltriphcnol Plastics triphcnol [C] 0.32 0 
520-36-5 Apigenin Flavone genistcin-like 0.31 0 
80-46-6 4-(2-Methy\butan-2-yl)phenol Chemical 1\.->J.Ctant phenol alkyl 0.28 0 
17696-62-7 Phenylparaben Microbicide paraben 0.28 0 
1219-38-1 Octylparaben Microbicide paraben 0.27 0 
131-56-6 2,4-Dihydroxybenzophenone UV-ab:;orber phenol-phenyl [CO] 0.27 0 
80-09-1 4,4'-Sulfonyldiphenol Chemical reactant phenol-phenol [S02] 0.26 0 
520-18-3 Kaempferol Flavone genistein-like 0.25 0 
6088-51-3 6-Hrdroxy-2-naphthyl disulfide Unknown phenolnaphthalene-phenolnaphtha \enc 0.25 0 
[SS] alcohol 
5349-51-9 4-(2-Methylbutan-2-yl)cyclohexanol Fragrance a.gent alcohol sec alkane cyclo 0.25 0 
53-19--0 o,p'-DDD Pesticide degradate phenyl-phenyl [C] chloro 0.24 0 
92-69-3 4-Phcnylphenol Chemical reactant phenol-phenylpheno\.2 0.22 0 
94.13.3 Propylparabcn Microbicide paraben 0.21 0 
63-05·8 4-Androstene-3, 17-dione Pha:muccutical steroid A 0.18 0 
126-00-1 Diphenolic acid Plasticizer phenol-phenol [q carbox_ylic acid 0.17 0 
31 
99-71-8 4-{Butan-2-yl)phcnol Chemical intennediate phenol alkyl 0.16 0 
98-54-4 4-tcrt-Butylphcnol Plas!icizcr phenol alkyl 0.16 0 
14816-18-3 Phoxim Insecticide phenyl thiophosphate nitrilc 0.16 0 
2919-66-6 Mclcngestrol acetate Phannaccutica! steroid P 0.16 0 
124-22-1 J-Dodccanamine Surfactant amine pri 0.15 0 
6683-19-8 Irganox 1010 Antiol'idant phenol carboxylate chelator4 0.15 0 
51-52-5 6-Propyl-2-thiouraci! Pharmaceutical uracil 0.14 0 
612-82-8 3,3'-Dimethylbenzidine dihydrochloride Chemical reactant (dyes) aniline-aniline 0.14 0 
4712-554 Diphcnyl phosphite Stabilizer (PVC) phenyl phosphate 0.14 0 
141-79-7 4-.l\1ctbylpcnt-3-en-2-one Solvent ketone enc 0.14 0 
2/3/6893 3 ,5 ,J'-Triiodothyroninc Pham1aceutical phenol-phenyl [OJ iodo carboxylic 0.14 0 
acid 
6055-19-2 Cyclophosphamidc monohydrate Pharmaceutical phosphamide 0.14 0 
480-40-0 chry~in Fiavone phenol ~nzopyran 0.13 0 
3319-31-1 Tris{2-cthylhexyl) trimel!itate Plastic>. phthalate 0.12 0 
1638-22-8 4-Butylph!.'nol unknov.n phenol alkyl 0.11 0 
140-I0-3 Cinnarnic acid Flavor agent/Fragrance phenyl carboxylic acid O.IO 0 
agent 
960-71-4 Triphcnylborane Chemical intcm1ediate triphenyl [B] 0.10 0 
50-41-9 Clomiphenc citrate Phamiacentical tamoxifen-llke 0.03 0.59 
54965-24-1 Tamoxifen citrate Pham1aceutic<1! tamoxifi:n-like 0.03 0.55 
82640-04-8 Raloxifene hydrochloride Pharmaceuticill phenol-phenol 0.02 0.67 
10540-29-1 Tamoxifen Pharrnaceutic<1l tamoxifcn-like 0.02 0.45 
68392-35-8 4-Hydroxytamoxifen Pharmaceutical tamoxifcn-likc 0.01 0.69 
90357-06--5 Bkalutamide Pharmaceutical Jlutamide-Jike 0.003 OJI 
84371-65-3 Mifepristonc Pharmaceutical steroid P 0.003 031 
129453-61-8 Fulvestrant Phannaceulical stcroidE 0 0.64 
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Figure 1: (A) Graphical representation of the computational network used in the in vitro analysis of the ER 
pathway across assays and technology platforms. Colored arrow nodes represent "receptors" with which a 
chemical can directly interact. Colored circles represent intermediate biological processes that are not 
directly observable. White stars represent the in vitro assays that measure activity at the biological nodes. 
Arrows represent transfer of information. Gray arrow nodes are the pseudo-receptors. Each in vitro assay 
(with the exception of Al 6) has an assay-specific pseudo-receptor, but only a single example is e:"<plicitly 
shown, for assay AI. (B) Patterns of assays that would be activated when specific receptors are activated 
by the chemical, in particular RI, R2 and R6. The activating chemical in its receptor are circled in pink, and 
the activated assays and the pathways to them are also highlighted in pink. 
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Figure l: (A) Graphical representation of the computational network used in the in vitro analysis of the ER 
pathway across assays and technology platforms. Colored arrow nodes represent "receptors" with which a 
chemical can directly interact. Colored circles represent intermediate biologkal processes that are not 
directly observable. White stars represent the in vitro assays that measure activity at the biological nodes. 
Arrows represent transfer of information. Gray arrow nodes are the pseudo-receptors. Each in vitro assay 
{with the exception of A16) has an assay-specific pseudo-receptor, but only a single example is explicitly 
shown, for assay AL (B) Patterns of assays that would be activated when specific receptors are activated 
by the chemical, in particular RI, R2 and R6. The activating chemical in its receptor are circled in pink, and 
the activated assays and the pathways to them are also highlighted in pink. 
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Figure 2·. Two-way hierarchical clustering of chemical activity across the 18 in vitro assays used to test for 
ER activity, Assays and technologies arc aligned across the x-axis, where the "A" and "R" values refer to the 
assay and receptors/pseudo-receptors from Figure I and Table I .Chemicals are aligned along the y-axis. 
The heatmap shows ~loglO(AC50) values for all assays and all chemicals with at least one assay hit. Darker 
red indicates more potent activity (lower AC50), while white represents inactive chemical-assay pairs. Note 
that the assays cluster by technology I pseudo-receptor. 
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Figure 3: Results of the model for three prototype chemicals. For each chemical, the left-hand panel shows 
the synthetic concentration-response data for the 18 assays, colored by assay groups defined in the legend. 
The righ I-hand panel shows the corresponding magnitude of the modeled receptor responses. The agonist 
receptor (RI) is designated by blue, the antagonist receptor (R2) by red and the other pseudo-receptors are 
colored as indicated in the legend. AUC values for the agonist (RI) and antagonist (R2) receptors are 
provided below the chemical name. For chemicals with cell-stress I cytoto:dcity activity (2 or more 
cytotoxicity hits, see Methods), the cell-stress I cytotoxicity center is indicated by a vertical red line, and the 
cell-stress I cytotoxicity region (starting 3 cell-stress I cytotoxicity MAD below the cell-stress I cytoto:dcity 
center) is indicated by the gray shaded region. A green horizontal bar indicates the median-AC50 of the 
active assays. Similar plots for all chemicals are given in Supplemental File S3. 
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Figure 3: Results of the model for three prototype chemicals. For each chemical, the left-hand panel shows 
the synthetic concentration-response data for the I 8 assays, colored by assay groups defined in the legend. 
The right-hand panel shows the corresponding magnitude of the modeled receptor responses. The agonist 
receptor (RI) is designated by blue, the antagonist receptor (R2) by red and the other pseudo-receptors are 
colored as indicated in the legend. AUC values for the agonist (RI) and antagonist (R2) receptors are 
provided below the chemical name. For chemicals with cell-stress I cytotoxicity activity (2 or more 
cytoto:dcity hits, see Methods), the cell-stress I cytotoxicity center is indicated by a vertical red line, and the 
cell-stress I cytotoxicity region (starting 3 cell-stress I cytotoxicity MAD below the cell·stress I cytotoxicity 
center) is indicated by the gray shaded region. A green horizontal bar indicates the median-AC50 of the 
active assays. Similar plots for all chemicals are given in Supplemental File S3. 
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Figure 4: Plots showing activity ofthe agonist (top) and antagonist (bottom) reference chemicals. Chemicals 
that are intended to be positive are indicated by green circles, while those intended to be inactive are 
indicated by red circles. For the agonists, the expected potency range is also indicated (middle column). For 
chemicals with one or more pseudo-receptor AUC values greater than zero, the value is indicated by an X, 
and the pseudo-receptor name is indicated. The inset shows the assay curves for dibutyl phthalate, as 
described in the text (colored based on Figure 3). 
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Figure 5: Plot of the maximum AUC vs. minimum-AC50 values. Each point is a single chemical that was 
active in at least one assay. The AUCvalue given is the maximum of the AUC(agonist) and AUC(antagonist) 
values for the chemical. The dashed line is the best-fit for AUC(agonist) values >0.1. Chemicals are labeled 
in order: black circle, at least one AUC>O.I; green up-triangle, positive agonist reference chemical; green 
down-triangle, positive antagonist reference chemical; red diamond, negative reference chemical; cyan 
circle, example chemicals with AUC significantly below the fitted line but above 0.1. The vertical line at JOO 
µM indicates the highest concentration tested, while the horizontal line at AUC=O. l indicates an approximate 
threshold between chemicals with clear agonist I antagonist activity and those that are potentially active 
through interference processes. The inset shows graphs of assay activity for 4·androstene·3, 17-dione 
(colored based on Figure 3). 
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Figure 6: Histogram ofZ-scores for the assay ATO_ERa_TRANS_up. The Z-score is defined as the distance 
between the median cytoto:dcity concentration and a chemical's ACSO in this assay, in units of global 
cytotoxicity 1\tAD, for all chemicals active in this assay. One can see a bimodal distribution with one peak at 
zero (marked with a heavy red line) and another with a peak near 6. \Ve hypothesize that chemicals active 
in the low-Z region are more likely to be false positives and less likely to be estrogenic than those active in 
the high-Z region. 
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Figure 7: Dar chart showing the fraction of chemicals remaining for each of them ulti-assay receptors/ 
pseudo-receptors after filtering for efficacy (T) and cytoto:dcity (Z-score). The receptors were limited to 
those with 5 or more chemicals with AUC>O.l from Table 2. lfthere were no chemicals for a pseudo-
receptor in a given AUC bin, a small negative bar is shown. The legend indicates AUC ranges corresponding 
to Table 2. 
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